Ilyang Pharmaceutical Co.,Ltd (007575) - Net Assets

Latest as of June 2026: ₩256.94 Billion KRW ≈ $174.12 Million USD

Based on the latest financial reports, Ilyang Pharmaceutical Co.,Ltd (007575) has net assets worth ₩256.94 Billion KRW (≈ $174.12 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩451.72 Billion ≈ $306.13 Million USD) and total liabilities (₩194.78 Billion ≈ $132.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 007575 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩256.94 Billion
% of Total Assets	56.88%
Annual Growth Rate	2.53%
5-Year Change	-11.17%
10-Year Change	11.07%
Growth Volatility	13.38

Ilyang Pharmaceutical Co.,Ltd - Net Assets Trend (2014–2025)

This chart illustrates how Ilyang Pharmaceutical Co.,Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Ilyang Pharmaceutical Co.,Ltd stock valuation.

Annual Net Assets for Ilyang Pharmaceutical Co.,Ltd (2014–2025)

The table below shows the annual net assets of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025. Also explore how fast is Ilyang Pharmaceutical Co.,Ltd growing its equity to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	₩241.41 Billion ≈ $163.60 Million	+0.78%
2024-12-31	₩239.53 Billion ≈ $162.33 Million	+21.96%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	-32.70%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	+7.39%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	+10.96%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	+9.96%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	+6.13%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	-0.52%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	-2.93%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	+3.01%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	+15.01%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Ilyang Pharmaceutical Co.,Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 12960028724000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩122.79 Billion	51.68%
Other Components	₩114.81 Billion	48.32%
Total Equity	₩237.60 Billion	100.00%

Ilyang Pharmaceutical Co.,Ltd Competitors by Market Cap

The table below lists competitors of Ilyang Pharmaceutical Co.,Ltd ranked by their market capitalization.

Company	Market Cap
ITEK Inc KQ:119830	$92.33 Million
Ubiquoss Holdings Inc KQ:078070	$92.34 Million
Freeman Gold Corp V:FMAN	$92.35 Million
FG Merger II Corp. Unit NASDAQ:FGMCU	$92.35 Million
JAKS Resources Bhd KLSE:4723	$92.31 Million
Western Asset Investment Grade Defined Opportunity Closed Fund NYSE:IGI	$92.30 Million
Cardiff Oncology Inc NASDAQ:CRDF	$92.29 Million
Maronan Metals Ltd AU:MMA	$92.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ilyang Pharmaceutical Co.,Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 235,951,178,730 to 237,603,084,110, a change of 1,651,905,380 (0.7%).
Net income of 6,904,778,960 contributed positively to equity growth.
Dividend payments of 2,880,502,710 reduced retained earnings.
Share repurchases of 1,000,007,270 reduced equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩6.90 Billion	+2.91%
Dividends Paid	₩2.88 Billion	-1.21%
Share Repurchases	₩1.00 Billion	-0.42%
Other Changes	₩-1.37 Billion	-0.58%
Total Change	₩-	0.70%

Book Value vs Market Value Analysis

This analysis compares Ilyang Pharmaceutical Co.,Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.57x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 0.71x to 0.57x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩10566.65	₩7500.00	x
2018-12-31	₩10298.48	₩7500.00	x
2019-12-31	₩10815.48	₩7500.00	x
2020-12-31	₩11381.04	₩7500.00	x
2021-12-31	₩12310.50	₩7500.00	x
2022-12-31	₩12973.71	₩7500.00	x
2023-12-31	₩10928.67	₩7500.00	x
2024-12-31	₩13098.64	₩7500.00	x
2025-12-31	₩13255.43	₩7500.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ilyang Pharmaceutical Co.,Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 2.91%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 2.53%
• Asset Turnover: 0.60x
• Equity Multiplier: 1.92x
Recent ROE (2.91%) is above the historical average (2.50%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-6.36%	-5.18%	0.49x	2.50x	₩-28.19 Billion
2015	2.28%	1.84%	0.55x	2.23x	₩-14.97 Billion
2016	2.96%	2.26%	0.61x	2.16x	₩-14.06 Billion
2017	3.26%	2.32%	0.62x	2.27x	₩-12.93 Billion
2018	-2.61%	-1.63%	0.69x	2.31x	₩-23.64 Billion
2019	5.07%	3.08%	0.74x	2.22x	₩-9.70 Billion
2020	5.25%	3.17%	0.78x	2.12x	₩-9.84 Billion
2021	6.42%	3.87%	0.75x	2.21x	₩-8.03 Billion
2022	8.20%	5.01%	0.77x	2.12x	₩-4.23 Billion
2023	-1.23%	-0.90%	0.75x	1.82x	₩-22.05 Billion
2024	3.83%	3.36%	0.62x	1.83x	₩-14.56 Billion
2025	2.91%	2.53%	0.60x	1.92x	₩-16.86 Billion

Industry Comparison

This section compares Ilyang Pharmaceutical Co.,Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $514,702,171,378
Average return on equity (ROE) among peers: 2.68%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Ilyang Pharmaceutical Co.,Ltd (007575)	₩256.94 Billion	-6.36%	0.76x	$92.33 Million
Dongwha Pharm.Co.Ltd (000020)	$297.40 Billion	3.39%	0.25x	$95.24 Million
Yuhan Corp. (000100)	$1.65 Trillion	3.48%	0.32x	$3.87 Billion
Yuhan Corp Preferred (000105)	$1.65 Trillion	3.48%	0.32x	$45.29 Million
Yuyu Pharma (000220)	$128.69 Billion	-1.72%	0.50x	$42.22 Million
Yuyu Pharma Inc (000225)	$140.54 Billion	5.80%	0.47x	$14.69 Million
Yuyu Pharma Inc (000227)	$135.06 Billion	6.46%	0.54x	$30.10 Million
Ildong Holdings Co Ltd (000230)	$332.95 Billion	3.56%	0.86x	$47.00 Million
Samil Pharm (000520)	$56.08 Billion	-15.27%	1.64x	$107.47 Million
Donga Socio Holdings (000640)	$580.35 Billion	10.90%	0.82x	$405.77 Million
Jw Pharmac (001060)	$172.48 Billion	6.75%	1.99x	$426.35 Million

About Ilyang Pharmaceutical Co.,Ltd

KO:007575 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$92.33 Million

₩136.24 Billion KRW

Market Cap Rank

#19573 Global

#993 in Korea

Share Price

₩7500.00

Change (1 day)

+0.94%

52-Week Range

₩7000.00 - ₩12980.00

All Time High

₩141909.13